First global data, from Rosetta Lung-02 in first-line NSCLC, tell a familiar story.
ApexOnco Front Page
Recent articles
Silevertinib efficacy comes close to firmonertinib’s, but toxicity is a new worry.
Though lung cancer looks promising a partner is now needed.
Deteriorating efficacy and a treatment-related death with Zynlonta plus Columvi spook investors.
A more comprehensive dataset on JANX007 sends the group’s stock down.
But the group still hopes to get IGV-001 approved based on overall survival data.
The agency approved eight oncology products over the month.
Car-T therapies and ADCs feature among recent first-in-human study entrants.